Future Family, Inc. is a subscription-based fertility service founded in 2016 and headquartered in San Francisco, California. The company provides comprehensive plans that cover all healthcare costs related to fertility, including in vitro fertilization (IVF) and egg freezing. Clients benefit from personalized fertility planning, clinic matching, and dedicated nurse concierge support. Future Family emphasizes accessibility with 24/7 access to a care team and offers a digital health platform to facilitate communication and care management. Their services also encompass clinic visits, medical procedures, laboratory work, and medication delivery, thereby creating a streamlined and stress-free experience for individuals and couples seeking fertility solutions.
PayGround provides healthcare businesses of all sizes a modernized payment solution in which they can easily upload their A/R and trigger digital-first requests for payment (via a mix of email/text/U.S. Mail). Patients can make payments in just a matter of a few seconds.
Brightside Health is a telemedicine platform that offers evidence-based mental health treatments. Brightside Health provides a personalized treatment experience for members through video visits, messaging, ongoing support, and medication delivery. With a care model encompassing precision psychiatry, a clinically proven approach to therapy, and continuous care monitoring from a network of world-class providers, Brightside Health members feel better faster and stay that way longer. Brightside was founded in 2017 and is headquartered in San Francisco, California, United States.
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.
Monogoto is a cloud-based cellular network. Its API-driven Infrastructure-as-a-Service was designed from the ground up with simplicity in mind to enable cellular connectivity with existing enterprise IT infrastructure. With hundreds of ready-to-use APIs, Monogoto offers cellular connectivity with edge to the cloud security for IoT, Private LTE, and 5G use cases. Its services include full audit for all network events with anomaly detection and alerts automation. Monogoto’s enterprise-friendly solution enables customers to consume advanced cellular VAS with zero CAPEX and an “as-a-Service” business model. The Monogoto network is distributed globally with public connectivity in 180 countries. Helping companies to comply with regulation, the Monogoto solution supports on-premise local breakout topology for private LTE/5G networks.
TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.
Grin is a comprehensive digital orthodontic platform providing teeth straightening for all types of patients with a real local orthodontist. The platform also connects patients with a real orthodontist from the convenience of their smart device. They deliver responsible care from orthodontic specialists in an easily accessible and cost-effective way, Grin provides patients quality care that results in an exceptional smile together with all of the modernized convenience that they expect. Grin technology, aligned with a network of local trusted orthodontists, ensures that every patient gets the right care. The platform Grin App and Grin Scope is a patent-pending technology that offers remote monitoring for a variety of orthodontic needs. The Grin experience includes high-quality self-scans with the latest teeth straightening solutions. Practitioners and patients can now use these telemedicine tools to achieve a new, more convenient treatment journey. It was founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019 and is based in New York and Austin.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
PayGround provides healthcare businesses of all sizes a modernized payment solution in which they can easily upload their A/R and trigger digital-first requests for payment (via a mix of email/text/U.S. Mail). Patients can make payments in just a matter of a few seconds.
BurnAlong is a personalized wellbeing class and social motivation to help people get the health and wellness they need. BurnAlong delivers personalized corporate wellness classes and social motivation to help employees achieve their health and wellness goals; and companies in turn create great cultures that retain and attract talent. It was founded in 2016 and is headquartered in Baltimore, Maryland.
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications. By addressing the major challenges of medication management utilizing a data science-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%. Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc.
Genoox uses the power of the community to make genomic data actionable, with a mission of creating the largest real world evidence network of genomic and clinical data. Genoox’s cloud-based AI platform connects clinicians, genetic counselors, and healthcare organizations to create a network effect by sharing genetic insights, enabling platform users to make impactful discoveries using the most advanced genomic tools and applications. Genoox is used by over 1,700 health organizations, hospitals and medical facilities in 44 markets across the globe Amir Trabelsi and Moshe Einhorn founded Genoox in 2014, with its headquarters in Palo Alto in California.
V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.
BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CE marked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US.
TuneFork is audio personalization technology software that delivers an optimal hearing experience anywhere you go, bringing out the very best from your mobile sound system. Hearing is an individual experience. Each of us has unique hearing “earprints”. This is why no one sound system is perfect for everyone. When you listen to unbalanced audio, you will always miss something. In some cases, you may even cause damage to your hearing. TuneFork guides you through a simple test which characterizes your hearing, creating a personal Audio Profile. Because our self-test is clinically accurate, it provides the best results possible, truly the Gold Standard in Audio experience. We use the test results to tailor a precise audio filter for each and every user, creating the perfect match between your sound system and your hearing. TuneFork can be integrated into any operating or network and optimize all audio content: *Phone calls *Music *Video *Voice messages *Rings & Alerts. With the spread of IoT more and more "smart" devices can carry TuneFork's advanced audio technology – smart TVs, smart cars, other smart devices, but above all: smartphones. Smartphone sales stood at 1.5 billion units in 2016. Their use extends far beyond two-way communication and includes music, video viewing, social networking and gaming. Any user can benefit from using TuneFork. For some it will break barriers created by hearing impairment, while for others it will deliver an improved audio experience from their device. Comparative Advantage A software only solution The most accurate self-test results Product proven by clinical tests in laboratory conditions 2 Patent pending
Latica (formerly Lynx.MD) is a visionary healthcare data company dedicated to revolutionizing medical research and innovation. Founded in 2019, Latica provides a secure and collaborative data ecosystem where life sciences organizations, healthcare providers, and researchers can harness the power of clinical and operational data to drive meaningful advancements in medicine. Our platform leverages cutting-edge AI, computer vision, and data analytics to unlock the potential of siloed healthcare data, enabling groundbreaking discoveries while prioritizing security and privacy. Latica empowers collaboration across the healthcare ecosystem, delivering actionable insights that improve outcomes for patients, providers, and researchers alike. Join us in shaping the future of healthcare innovation through the power of data. Learn more at www.latica.ai.
Cala Health is a bioelectronic medicine company focused on developing wearable neuromodulation therapies for chronic diseases. The company integrates neuroscience and technology to provide individualized peripheral nerve stimulation. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor. Cala Health is also working on therapies for Parkinson's disease and other neurological conditions and areas in psychiatry, cardiology, and autoimmune disorders.
TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.
Latica (formerly Lynx.MD) is a visionary healthcare data company dedicated to revolutionizing medical research and innovation. Founded in 2019, Latica provides a secure and collaborative data ecosystem where life sciences organizations, healthcare providers, and researchers can harness the power of clinical and operational data to drive meaningful advancements in medicine. Our platform leverages cutting-edge AI, computer vision, and data analytics to unlock the potential of siloed healthcare data, enabling groundbreaking discoveries while prioritizing security and privacy. Latica empowers collaboration across the healthcare ecosystem, delivering actionable insights that improve outcomes for patients, providers, and researchers alike. Join us in shaping the future of healthcare innovation through the power of data. Learn more at www.latica.ai.
V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.
VI is the leading Enterprise-AI platform in the health sector. Vi helps health enterprises leverage Data & AI to maximize member health outcomes and financial returns
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize pci therapy decisions and elevate coronary angiography from visual assessment to an objective FFRangio-based decision-making tool for physicians.
Colospan is a clinical-stage medical device company developing proprietary technology for colorectal surgery to prevent anastomotic leaks and diverting colonic stomas. It has developed a product that protects the intestine after a colectomy and sealing of the intestine, which is performed in cases of severe intestinal inflammatory disease and cancer of the bowel or rectum. In places where the intestine has been sealed, leakage requiring prolonged hospitalization or repeat surgery on already weak patients is liable to occur. The company develops a device that prevents inner-body leaks after intestinal surgery. It also develops a silicone-based, tube-like device intended to prevent the leak of feces into the body cavity after surgery in the intestines or colon. Colospan's device is meant to prevent or delay the for need colostomy—the surgical creation of an external bypass for the intestine or colon following the removal of a diseased part. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site. Colospan was founded in 2010 and is based in Kefar Sava, Israel.
Perfect for backyard parties, BBQs, tailgating, or karaoke in the park, the ZingBox is a solar powered boom box with throwback style.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications. By addressing the major challenges of medication management utilizing a data science-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%. Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc.
OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.
VI is the leading Enterprise-AI platform in the health sector. Vi helps health enterprises leverage Data & AI to maximize member health outcomes and financial returns
V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.
6over6 offers a digital healthcare platform that enables users to perform their own eye vision test. They have reimagined all fundamental optometric tools and fitted them into smartphone, enabling a complete and accurate measurement of the refractive error of the eye, for eyeglasses and contact lens prescription, using software. GlassesOn is registered as a Class 1 Exempt Medical Device on the FDA Medical Device Listings. However, GlassesOn does not provide medical advice, and does not replace a full eye health exam.
Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery (MRCAS). The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view.
OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.
Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications. By addressing the major challenges of medication management utilizing a data science-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%. Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc.
BioGaming provides an end-to-end solution for improving rehabilitation outcomes. BioGaming is win-win for both the user and the therapist. The platform incorporates home based gaming consoles and 3D sensing technologies to track patient performance, and applies sophisticated machine learning algorithms to provide detailed quantitative and qualitative reports.
Cardiva Medical is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The company’s products include VASCADE, a vascular closure system, and Catalyst II and Catalyst III, which are designed to aid manual compression. It was founded in 2002 and headquartered in Sunnyvale, California.
Apica Cardiovascular is a pre revenue medical device company commercializing a technology for access and closure of the heart’s apex and the peripheral vascular system. The underlying technology has applications in a number of medical procedures such as Transcatheter Heart Valves (TAVI), AAA, and LVAD implantation. The technology standardizes access and closure for large bore therapeutic devices without loss of blood via minimally invasive surgical or percutaneous access on the beating heart. The technology has progressed to the point where it has proven the initial concept in animal and cadaver models and is now moving toward initial clinical trials.
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications. By addressing the major challenges of medication management utilizing a data science-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%. Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc.
Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.
Cardiva Medical is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The company’s products include VASCADE, a vascular closure system, and Catalyst II and Catalyst III, which are designed to aid manual compression. It was founded in 2002 and headquartered in Sunnyvale, California.